Is Ascendis Pharma A/S (NASDAQ:ASND) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Ascendis Pharma A/S at current levels.
Two rare-disease franchises ramping fast, a TransCon platform with optionality the market still treats as a one-product story.
Where ASND is headed
Ascendis exits 2027 with two commercial drugs running at a combined $2.2-2.5B revenue pace, not the $1.3B the sell-side currently models. SKYTROFA keeps grinding share in pediatric growth hormone deficiency against daily injections, but YORVIPATH is the franchise that reshapes the company. Chronic hypoparathyroidism has roughly 80,000 diagnosed adult patients in the US and EU5 who have been treated as an afterthought for decades, mostly with calcium and active vitamin D, mostly badly. YORVIPATH is the first therapy that actually replaces the missing hormone on a physiologic basis. At a US list around $145,000 a year and capture rates climbing through 2026 as supply constraints fully resolve, this becomes a $1.5B+ drug exiting 2027 with a clear line of sight to $3B at peak.
Read the full Compass Direction on ASND
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $218.06).
See the full ASND analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Ascendis Pharma A/S (NASDAQ:ASND) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Ascendis Pharma A/S at current levels. Two rare-disease franchises ramping fast, a TransCon platform with optionality the market still treats as a one-product story.
What is ASND's Compass Score?
Ascendis Pharma A/S scores 77/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for ASND?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ASND page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.